WATERTOWN, Mass., July 14, 2016 (GLOBE NEWSWIRE) — pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced that the results from an investigator-sponsored Phase 2 study of pSivida’s Medidur showed no recurrence of uveitis in 11 eyes treated with Medidur during the two years following implantation, while six of 10 fellow eyes without Medidur experienced recurrence. Furthermore, although visual acuity typically declines over time in uveitis patients, all Medidur-treated eyes had a significant improvement in mean visual acuity compared to baseline throughout the two years, and mean visual acuity showed successive improvement at two years over one year.
Read the entire article here.